Company / Cash & Equivalents
Supernus Pharmaceuticals, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$128.4M
FY2025
5-year range
$69.3M / $203.4M
FY2021-FY2025
Trend
+85.3%
vs FY2024
Sector context
#124 of 207
Health Care
What the data says
At $128M, Supernus Pharmaceuticals, Inc.'s cash & equivalents ranks #124 of 207 in the Health Care sector. Cash & Equivalents returned to growth in FY2025 after 4 years of decline, reaching $128M.
Based on SEC 10-K filings.
$128M in FY2025 with a 5-year CAGR of -15.0%.
Improved from $75M to $128M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +11.3%
- 5-Year CAGR
- -15.0%
- 10-Year CAGR
- -
Sector benchmark
#124 of 207 in Health CareTop 60% of 207This company $128.4M Sector average $669.5M
▼
-80.8% below sector average
Key checks
Key Insights
- 5-year CAGR of -15.0%, indicating a declining trend.
- In FY2025, cash & equivalents increased 85.3% year-over-year.
- Ranks #124 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2020.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $128.4M | +85.3% |
| FY2024 | $69.3M | -7.6% |
| FY2023 | $75.1M | -19.4% |
| FY2022 | $93.1M | -54.2% |
| FY2021 | $203.4M | -29.5% |
| FY2020 | $288.6M | +59.1% |
| FY2019 | $181.4M | -5.7% |
| FY2018 | $192.2M | +91.7% |
| FY2017 | $100.3M | +175.6% |
| FY2016 | $36.4M | +8.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026